Mavrilimumab

Mavrilimumab is a human monoclonal antibody that is designed for the treatment of rheumatoid arthritis. It is an immunoglobulin G4, anti-granulocyte macrophage colony-stimulating factor (GM-CSF) receptor α monoclonal antibody. Mavrilimumab was developed by MedImmune, a subsidiary of AstraZeneca.

Mechanism of Action

Mavrilimumab works by binding to the alpha chain of the GM-CSF receptor, inhibiting GM-CSF signaling. GM-CSF is a cytokine that plays a crucial role in inflammation and autoimmunity, including the pathogenesis of rheumatoid arthritis.

Clinical Trials

Mavrilimumab has undergone Phase IIb clinical trials for rheumatoid arthritis. The results showed that the drug was well-tolerated and led to improvements in disease activity. It is currently undergoing Phase III trials.

COVID-19 Treatment

In 2020, mavrilimumab was investigated as a potential treatment for COVID-19. Preliminary results from a small, single-center, open-label study in Italy suggested that mavrilimumab may reduce the risk of respiratory failure and death in patients with severe COVID-19 pneumonia.

See Also

• List of investigational drugs
• Monoclonal antibodies
• Rheumatoid arthritis

Mavrilimumab Resources
Latest articles Most recent articles Ongoing trials	Wikipedia